A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in adults with type 2 diabetes who also have obesity or are overweight to see how it affects their body weight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 938 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-03 · est. completion 2023-04

Where 75 sites · Argentina, Brazil, India, Japan, Puerto Rico, Russia, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT04657003 ↗

Description as written by the study sponsor.

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Other

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes, Overweight, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04657003 ↗